Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agrippal
- Development stage
- Phase 4
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Agrippal is an inactivated influenza vaccine containing surface antigens (haemagglutinin and neuraminidase) of influenza virus types A and B. It works by causing the body to produce antibodies against the influenza virus strains contained in the vaccine. The vaccine is reformulated annually to match the prevalent strains for each flu season. Protection typically develops within 2-3 weeks after vaccination and lasts for approximately 12 months.
- Brand names
- AgrippalAgrippal S1
02
Targets
HA0 (Influenza B virus hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on agrippal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agrippal.